Ipca Laboratories is making a strong comeback in the US generics market after resolving regulatory issues and acquiring Unichem. The Mumbai-based pharmaceutical company aims to achieve $200 million (₹1,675 crore) in US revenue over the next 12-18 months, according to Managing Director Ajit Kumar Jain.
Previously, Ipca faced regulatory setbacks that slowed down its US operations, but now all their plants have cleared inspections, allowing them to focus on the US market again. With over 40 products already filed for approval, Ipca is ready to commercialize these in the US. Before the import ban in June 2017, Ipca’s US business generated around $30-$35 million annually.
Ipca has a busy launch schedule planned, with 12-13 new products set to hit the US market in the next two years. Unichem, which Ipca recently acquired for around ₹1,600 crore, will also be launching 5-6 new products in FY25. Despite Unichem’s past struggles, Ipca is confident in turning the business around by cutting costs and improving efficiency. Unichem has already reported a net profit of ₹22 crore for the first quarter of fiscal 2025.
Ipca plans to expand Unichem’s business beyond the US and Brazil to other global markets, using the combined product portfolio of both companies. On a consolidated basis, Ipca’s revenue has grown 23% year-on-year to ₹7,829.8 crore.
Disclaimer: The views and investment tips expressed by investment experts on Sharepriceindia.com are their own and not those of the website or its management. Sharepriceindia.com advises users to check with certified experts before taking any investment decisions.
